Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

Parkinson's disease (PD) is a disabling neurodegenerative disease that affects approximately 10 million people worldwide, ...

Trailhead Biosystems Inc. ( a biotechnology company advancing human cell innovation, has secured $20 million in financing. Trailhead specializes in precisely differentiating induced pluripotent stem ...

Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.

Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) ...

The development of novel therapeutics offers great hope for the fight against widespread diseases such as cancer, but they ...

Developed at the Children's Hospital of Philadelphia (CHOP) and called Zynteglo, the medicine uses the patient's own stem ...

A Beachwood-based biotechnology company has secured $20 million in financing that will enable an expansion in personnel, ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and poster ...

Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14 ...

Congratulations to Karl-Johan Malmberg, who has been awarded King Olav V's Cancer Research Prize for 2025. The prize is ...